Updated with statement from Pfizer and current stock prices.
NEW YORK (TheStreet) -- U.S. regulators rejected Thursday a tamper-resistant painkiller from Pfizer (PFE) and Pain Therapeutics (PTIE), said U.S. Food and Drug Administration spokesperson Shelly Burgess Thursday night.
The Pfizer-Pain Therapeutics drug, Remoxy, is a long-acting opioid consisting of the narcotic oxycodone mixed with ingredients aimed at making it resistant to abuse and misuse.
Pfizer confirmed Remoxy's rejection in a statement issued Friday morning but would not disclose the reasons for why FDA decided against approval.Durect Corp. (DRRX) is also responsible for some of the drug technology used in Remoxy and would have received royalties on sales had the drug been approved. Pain Therapeutics closed Thursday at $9.24 a share but was down 35% to $6 a share in early Friday trading. Durect shares closed Thursday at $3.09 but were off 32% to $2.10 early Friday. Pain Therapeutics has been seeking Remoxy's approval for more than three years and the drug was rejected by FDA once before, in 2008. Pfizer came on board the project when it acquired King Pharmaceuticals last year. King partnered with Pain Therapeutics in 2005 to help with Remoxy's development. Pfizer and Pain Therapeutics could not be reached for comment Thursday night so it's not known what steps need to be taken at this time for Remoxy to be resubmitted for approval again. Purdue Pharma already sells a tamper-resistant, long-acting form of oxycodone, so Remoxy's setback is a win for the privately held drug maker. Last Friday, FDA approved Oxecta, a short-acting, tamper-resistant painkiller from Pfizer and Acura Pharmaceuticals (ACUR). --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV